Severe psoriasis pustulosa palmaris et plantaris (Barber-Königsbeck) treated successfully with soluble tumour necrosis factor receptor fusion protein (etanercept) [7]

Journal of the European Academy of Dermatology and Venereology

Volumn 21, Issue 2, 2007, Pages 255-257

  Kasche, A ^a   Pfab, F ^a   Hein, R ^a   Athanasiadis, G I ^a   Ollert, M ^a   Ring, J ^a   Eberlein konig B ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE; ETANERCEPT; ETRETIN; METHOTREXATE; MOMETASONE FUROATE; PSORALEN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CASE REPORT; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG COST; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEALTH INSURANCE; HOSPITAL ADMISSION; HUMAN; INJECTION SITE REACTION; LETTER; PRIORITY JOURNAL; PUSTULE; PUSTULOSIS PALMOPLANTARIS; PUVA; QUALITY OF LIFE; SIDE EFFECT; XERODERMA;

BIOLOGICAL RESPONSE MODIFIERS; FEMALE; FOOT DERMATOSES; HAND DERMATOSES; HUMANS; IMMUNOGLOBULIN G; MIDDLE AGED; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 33846353226     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2006.01830.x     Document Type: Letter

References (9)

1. Eriksson MO, Hagforsen E, Lundin IP, Michaelsson G. Palmoplantar pustulosis: A clinical and immunohistological study. Br J Dermatol 1998; 138: 390-398.
2. Ettehadi P, Greaves MW, Wallach D, Aderka D, Camp RD. Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol 1994; 96: 146-151.
3. Mussi A, Bonifati C, Carducci M et al. Serum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis. J Biol Regul Homeost Agents 1997; 11: 115-118.
4. Moreland LW, Schiff MH, Baumgartner SW et al. Etanercept therapy in rheumatoid arthritis: A randomized, controlled trial. Ann Intern Med 1999; 130: 478-486.
5. Weinblatt ME, Kremer JM, Bankhurst AD et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253-259.
6. Mease PJ, Goffe BS, Metz J et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomized trial. Lancet 2000; 356: 385-390.
7. Weinberg JM, Ritu Saini BA. Biologic therapy for psoriasis: The tumor necrosis factor inhibitors infliximab and etanercept. Cutis 2003; 71: 25-29.
8. Gottlieb AB, Matheson RT, Lowe N et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003; 139: 1627-1632.
9. Lebwohl M. New developments in the treatment of psoriasis. Arch Dermatol 2002; 138: 686-688.